138 related articles for article (PubMed ID: 35805023)
1. Identifying Lethal Dependencies with HUGE Predictive Power.
Gimeno M; San José-Enériz E; Rubio A; Garate L; Miranda E; Castilla C; Agirre X; Prosper F; Carazo F
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805023
[TBL] [Abstract][Full Text] [Related]
2. Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.
Jaiswal A; Peddinti G; Akimov Y; Wennerberg K; Kuznetsov S; Tang J; Aittokallio T
Genome Med; 2017 Jun; 9(1):51. PubMed ID: 28569207
[TBL] [Abstract][Full Text] [Related]
3. DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies
Carazo F; Bértolo C; Castilla C; Cendoya X; Campuzano L; Serrano D; Gimeno M; Planes FJ; Pio R; Montuenga LM; Rubio A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645997
[TBL] [Abstract][Full Text] [Related]
4. Identifying synthetic lethal targets using CRISPR/Cas9 system.
Dhanjal JK; Radhakrishnan N; Sundar D
Methods; 2017 Dec; 131():66-73. PubMed ID: 28710008
[TBL] [Abstract][Full Text] [Related]
5. SuperDendrix algorithm integrates genetic dependencies and genomic alterations across pathways and cancer types.
Park TY; Leiserson MDM; Klau GW; Raphael BJ
Cell Genom; 2022 Feb; 2(2):. PubMed ID: 35382456
[TBL] [Abstract][Full Text] [Related]
6. Combined gene essentiality scoring improves the prediction of cancer dependency maps.
Wang W; Malyutina A; Pessia A; Saarela J; Heckman CA; Tang J
EBioMedicine; 2019 Dec; 50():67-80. PubMed ID: 31732481
[TBL] [Abstract][Full Text] [Related]
7. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.
Wang T; Yu H; Hughes NW; Liu B; Kendirli A; Klein K; Chen WW; Lander ES; Sabatini DM
Cell; 2017 Feb; 168(5):890-903.e15. PubMed ID: 28162770
[TBL] [Abstract][Full Text] [Related]
8. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.
Meyers RM; Bryan JG; McFarland JM; Weir BA; Sizemore AE; Xu H; Dharia NV; Montgomery PG; Cowley GS; Pantel S; Goodale A; Lee Y; Ali LD; Jiang G; Lubonja R; Harrington WF; Strickland M; Wu T; Hawes DC; Zhivich VA; Wyatt MR; Kalani Z; Chang JJ; Okamoto M; Stegmaier K; Golub TR; Boehm JS; Vazquez F; Root DE; Hahn WC; Tsherniak A
Nat Genet; 2017 Dec; 49(12):1779-1784. PubMed ID: 29083409
[TBL] [Abstract][Full Text] [Related]
9. Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.
Iorio F; Behan FM; Gonçalves E; Bhosle SG; Chen E; Shepherd R; Beaver C; Ansari R; Pooley R; Wilkinson P; Harper S; Butler AP; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
BMC Genomics; 2018 Aug; 19(1):604. PubMed ID: 30103702
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
12. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
14. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract][Full Text] [Related]
15. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
16. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
17. A CRISPR Competition Assay to Identify Cancer Genetic Dependencies.
Girish V; Sheltzer JM
Bio Protoc; 2020 Jul; 10(14):e3682. PubMed ID: 33659353
[TBL] [Abstract][Full Text] [Related]
18. Defining a Cancer Dependency Map.
Tsherniak A; Vazquez F; Montgomery PG; Weir BA; Kryukov G; Cowley GS; Gill S; Harrington WF; Pantel S; Krill-Burger JM; Meyers RM; Ali L; Goodale A; Lee Y; Jiang G; Hsiao J; Gerath WFJ; Howell S; Merkel E; Ghandi M; Garraway LA; Root DE; Golub TR; Boehm JS; Hahn WC
Cell; 2017 Jul; 170(3):564-576.e16. PubMed ID: 28753430
[TBL] [Abstract][Full Text] [Related]
19. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale CRISPR screening at high sensitivity with an empirically designed sgRNA library.
Henkel L; Rauscher B; Schmitt B; Winter J; Boutros M
BMC Biol; 2020 Nov; 18(1):174. PubMed ID: 33228647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
